Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach

References

• . World Health Organization. Diabetes fact sheet, http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed August 29, 2012
   Google Scholar
• . Katon WJ, Rutter C, Simon G, . The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28(11):2668–2672
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6): 1577–1596
   PubMed Web of Science ®Google Scholar
• . Foster GD, Sanders MH, Millman R, ; Sleep AHEAD Research Group. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–1019
   PubMed Web of Science ®Google Scholar
• . Heffner JE, Rozenfeld Y, Kai M, Stephens EA, Brown LK. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. Chest. 2012;141(6):1414–1421
   PubMedGoogle Scholar
• . Nadeau DA. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. Postgrad Med. 2010;122(3):7–15
   PubMed Web of Science ®Google Scholar
• . Carnethon MR, De Chavez PJ, Biggs ML, . Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308(6):581–590
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218–231
   PubMed Web of Science ®Google Scholar
• . Pi-Sunyer X, Blackburn G, Brancati FL, ; Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383
   PubMed Web of Science ®Google Scholar
• . Barnard ND, Cohen J, Jenkins DJ, . A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. Am J Clin Nutr. 2009;89(5):1588S–1596S
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Lilly Lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37(6):667–687
   PubMed Web of Science ®Google Scholar
• . Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE, ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services. Physical activity and health. A report of the Surgeon General. Executive summary. http://www.cdc.gov/nccdphp/sgr/pdf/execsumm.pdf. 2010. Accessed November 27, 2012
   Google Scholar
• . Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29(11):2518–2527
   PubMed Web of Science ®Google Scholar
• . Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968
   PubMed Web of Science ®Google Scholar
• . Praet SF, van Loon LJ. Optimizing the therapeutic benefits of exercise in type 2 diabetes. J Appl Physiol. 2007;103(4):1113–1120
   PubMedGoogle Scholar
• . Balducci S, Zanuso S, Cardelli P, ; Italian Diabetes Exercise Study (IDES) Investigators. Changes in physical fitness predict improvements in modifiable cardiovascular risk factors independently of body weight loss in subjects with type 2 diabetes participating in the Italian Diabetes and Exercise Study (IDES). Diabetes Care. 2012;35(6):1347–1354
   PubMedGoogle Scholar
• . Levinger I, Selig S, Goodman C, Jerums G, Stewart A, Hare DL. Resistance training improves depressive symptoms in individuals at high risk for type 2 diabetes. J Strength Cond Res. 2011;25(8):2328–2333
   PubMedGoogle Scholar
• . Sluik D, Buijsse B, Muckelbauer R, . Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. Arch Intern Med. 2012;172(17):1285–1295
   PubMedGoogle Scholar
• . Gibbs BB, Brancati FL, Chen H, . Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study [published online ahead of print September 25, 2012]. Eur J Prev Cardiol
   Google Scholar
• . Roden M. Exercise in type 2 diabetes: to resist or to endure? Diabetologia. 2012;55(5):1235–1239
   PubMedGoogle Scholar
• . Hansen D, Dendale P, Jonkers RA . Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patients. Diabetologia. 2009;52(9):1789–1797
   PubMedGoogle Scholar
• . Flack KD, Davy KP, Hulver MW, Winett RA, Frisard MI, Davy BM. Aging, resistance training, and diabetes prevention. J Aging Res. 2010;2011:127315
   PubMedGoogle Scholar
• . van Dijk JW, Manders RJ, Tummers K, . Both resistance- and endurance-type exercise reduce the prevalence of hyperglycaemia in individuals with impaired glucose tolerance and in insulin-treated and non-insulin-treated type 2 diabetic patients. Diabetologia. 2012;55(5):1273–1282
   PubMedGoogle Scholar
• . Colberg SR, Sigal RJ, Fernhall B, ; American College of Sports Medicine; American Diabetes Association. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care. 2010;33(12):e147–e167
   PubMed Web of Science ®Google Scholar
• . Bacchi E, Negri C, Zanolin ME, . Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). Diabetes Care. 2012;35(4):676–682
   PubMedGoogle Scholar
• . Grontved A, Rimm EB, Willett WC, Andersen LB, Hu FB. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012;172(17):1306–1312
   PubMedGoogle Scholar
• . Holloszy JO. Exercise-induced increase in muscle insulin sensitivity. J Appl Physiol. 2005;99(1):338–343
   PubMed Web of Science ®Google Scholar
• . Touvra AM, Volaklis KA, Spassis AT, . Combined strength and aerobic training increases transforming growth factor-betal in patients with type 2 diabetes. Hormones (Athens). 2011;10(2):125–130
   PubMedGoogle Scholar
• . Yardley JE, Kenny GP, Perkins BA, . Effects of performing resistance exercise before versus after aerobic exercise on glycemia in type 1 diabetes. Diabetes Care. 2012;35(4):669–675
   PubMedGoogle Scholar
• . Pan A, Sun Q, Bernstein AM, . Red meat consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. Am J Clin Nutr. 2011;94(4):1088–1096
   PubMed Web of Science ®Google Scholar
• . Aune D, Ursin G, Veierod MB. Meat consumption and the risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2009;52(11):2277–2287
   PubMed Web of Science ®Google Scholar
• . Barr SB, Wright JC. Postprandial energy expenditure in whole-food and processed-food meals: implications for daily energy expenditure. Food Nutr Res. 2010;54
   Google Scholar
• . Berkow SE, Barnard N. Vegetarian diets and weight status. Nutr Rev. 2006;64(4):175–188
   PubMed Web of Science ®Google Scholar
• . Barnard ND, Cohen J, Jenkins DJ, . A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006;29(8):1777–1783
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; America Diabetes Association; European Association for Study of Diabees. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L, ; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17( suppl 2):1–52
   PubMed Web of Science ®Google Scholar
• . Fortamet (metformin) [package insert]. Atlanta, GA: Shionogi Pharma, Inc; 2011
   Google Scholar
• . Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther. 2010;125(2):328–361
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579
   PubMed Web of Science ®Google Scholar
• . Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–830
   PubMed Web of Science ®Google Scholar
• . Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11(4):491–499
   PubMed Web of Science ®Google Scholar
• . Ferdaoussi M, Abdelli S, Yang JY, . Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes. 2008;57(5):1205–1215
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Vilsboll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci. 2012;32(14):4812–4820
   PubMed Web of Science ®Google Scholar
• . Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182–197
   PubMed Web of Science ®Google Scholar
• . Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156
   PubMed Web of Science ®Google Scholar
• . Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes. 2012;61(5):986–988
   PubMed Web of Science ®Google Scholar
• . Devries JH, Bain SC, Rodbard HW, ; Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35(7):1446–1454
   PubMed Web of Science ®Google Scholar
• . Bydureon (exenatide LAR) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2012
   Google Scholar
• . Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Ther Clin Risk Manag. 2010;6:401–411
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Cuddihy RM, Hanefeld M, ; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252–258
   PubMed Web of Science ®Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brandie M, . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Pratley R, Nauck M, Bailey T, ; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K, ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Wysham C, Macconell L, ; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Zinman B, Hoogwerf BJ, Durán Garcia S, . The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB, ; LEAD-4 Study Invesigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Diamant M, Van Gaal L, Stranks S, . Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35(4):683–689
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Buse JB, Nauck MA, Forst T, . Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract]. Diabetologia. 2011;54( suppl 1):S38
   Google Scholar
• . Davis S. Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus. S Afr Pharm J. 2012;79(3):22–26
   Google Scholar
• . Raz I, Hanefeld M, Xu L, ; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–2571
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386
   PubMed Web of Science ®Google Scholar
• . Gallwitz B. Linagliptin—a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes. 2012;5: 1–11
   PubMedGoogle Scholar
• . Janumet (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp; 2012
   Google Scholar
• . Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; Indianapolis, IN: Eli Lilly and Company; 2012
   Google Scholar
• . Onglyza (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2012
   Google Scholar
• . Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609–1629
   PubMed Web of Science ®Google Scholar
• . Vella A, Bock G, Giesler PD, . The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf). 2008;69(5):737–744
   PubMedGoogle Scholar
• . Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med. 2012;23(2):132–136
   PubMedGoogle Scholar
• . Pratley RE, Nauck M, Bailey T, ; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–1456
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Nauck MA Bailey T, . Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–1993
   PubMedGoogle Scholar
• . Wysham C, Bergenstal R, Malloy J, . DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705–714
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med. 2012;23(2): 126–131
   PubMedGoogle Scholar
• . Inzucchi SE. Management of hyperglycemia in T2DM: update on the new ADA-EASD position. http://www.guidelineadvantage.org/TGA/General/Management-of-Hyperglycemia-in-T2DM-Update-on-the-New-ADA-EASD-Position_UCM_441489_Article.jsp. July 13, 2012. Accessed September 10, 2012
   Google Scholar
• . Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–659
   PubMed Web of Science ®Google Scholar
• . Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22(12):2613–2619
   PubMed Web of Science ®Google Scholar
• . Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11(4):372–378
   PubMed Web of Science ®Google Scholar
• . Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56–64
   PubMed Web of Science ®Google Scholar
• . Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30(11):1976–1987
   PubMed Web of Science ®Google Scholar
• . Poon K, King AB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf. 2010;2:213–223
   PubMedGoogle Scholar
• . Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4(3):505–513
   PubMedGoogle Scholar
• . Pantalone KM, Kattan MW, Yu C, . Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14(9):803–809
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118
   PubMed Web of Science ®Google Scholar
• . Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract. 2003;9(5):406–416
   PubMedGoogle Scholar
• . Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–39
   PubMed Web of Science ®Google Scholar
• . Mamtani R, Haynes K, Bilker WB, . Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012;104(18):1411–1421
   PubMedGoogle Scholar
• . Defronzo RA. Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011;34(4):789–794
   PubMed Web of Science ®Google Scholar
• . Gaziano JM, Cincotta AH, O'Connor CM, . Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–1508
   PubMed Web of Science ®Google Scholar
• . Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8):1279–1284
   PubMed Web of Science ®Google Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Bolinder J, Ljunggren O, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031
   PubMed Web of Science ®Google Scholar
• . Heller S, Buse J, Fisher M, ; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1489–1497
   PubMed Web of Science ®Google Scholar
• . Garber AJ, King AB, Del Prato S, ; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507
   PubMed Web of Science ®Google Scholar
• . Herman WH. The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care. 2013;36(4):775–776
   PubMedGoogle Scholar
• . Rhee MK, Herrick K, Ziemer DC, . Many Americans have prediabetes and should be considered for metformin therapy. Diabetes Care. 2010;33(1):49–54
   PubMedGoogle Scholar
• . Misurski D, Lage MJ, Fabunmi R, Boye KS. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy. 2009;7(4):245–254
   PubMedGoogle Scholar
• . Fabunmi R, Nielsen LL, Quimbo R, . Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777–786
   PubMed Web of Science ®Google Scholar
• . Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy. 2009;29(11):1280–1288
   PubMed Web of Science ®Google Scholar
• . Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15( suppl 2):28–37
   PubMedGoogle Scholar
• . Foster GD, Borradaile KE, Sanders MH, ; Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–1626
   PubMedGoogle Scholar
• . Bennett WL, Wilson LM, Bolen S, ; Agency for Healthcare Research and Quality (US). Oral diabetes medications for adults with type 2 diabetes: an update. Comparative Effectiveness Reviews. No. 27. http://www.ncbi.nlm.nih.gov/books/NBK55754/. March 2011. Accessed November 27, 2012
   Google Scholar
• . Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385–411
   PubMed Web of Science ®Google Scholar
• . Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439–1451
   PubMed Web of Science ®Google Scholar
• . Byetta (exenatide LAR) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2012
   Google Scholar
• . Lantus (insulin glargine) [package insert]. Bridgewater, NJ: sanofi-aventis; 2010
   Google Scholar
• . Cycloset (bromocriptine) [package insert]. Tiverton, RI: VeroScience, LLC; 2010
   Google Scholar
• . Diabeta (glyburide) [package insert]. Bridgewater, NJ: sanofi-aventis; 2009
   Google Scholar
• . Amaryl (glimepiride) [package insert]. Bridgewater, NJ: sanofi-aventis; 2012
   Google Scholar
• . Actos (pioglitazone) [package insert]. Dublin, OH: Cardinal Health; 2011
   Google Scholar
• . Hanley AJ, Zinman B, Sheridan P, ; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of rosiglitazone and ramipril on ß-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care. 2010;33(3):608–613
   PubMedGoogle Scholar
• . Prandin (repaglinide) [package insert]. Dublin, OH: Cardinal Health; 2010
   Google Scholar
• . Starlix (nateglinide) [package insert]. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; 2011
   Google Scholar
• . Symlin (pramlinitide acetate) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2009
   Google Scholar
• . Glucotrol (glipizide) [package insert]. New York, NY: Pfizer Inc; 2003
   Google Scholar
• . Truven Health Analytics, http://thomsonreuters.com/products_services/healthcare/healthcare_products/clinical_deci_support/micro-medexclinicalevidencesols/medsafetysolutions/redbook/. Accessed November 27, 2012
   Google Scholar